On March 15, it was announced that Willkie client AXA Private Equity, Europe’s leading diversified private equity firm, agreed to the sale of its portfolio company CABB to private equity firm Bridgepoint Capital. Based in Germany, CABB is a fine-chemicals company with production facilities in Europe and Asia. It is one of the world’s leading suppliers of chemical building blocks based on chlorine and acetic acid and the world market leader in monochloroacetic acid (MCAA), an essential component used in a wide variety of applications ranging from herbicides and personal care to the food industry. Since being acquired by AXA in 2007, CABB has doubled it revenues to €311 million.
The Willkie team, led by partner Mario Schmidt included national partners Jan Wilms, Rolf Hünermann, Dr. Stefan Jörgens and Dr. Christian Rolf, and associates Dr. Octávio de Sousa, Dr. Markus Käpplinger, Ingo Bednarz, Tobias Daubert, Jennifer Diedrichsen, Tobias Dietrich, Abra Edwards (London), Jochen Riechwald, Dr. Maximilian Schwab, Kathrin Schwesinger and Dr. Matthias Werner.